Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I5TL
|
|||
| Former ID |
DCL000032
|
|||
| Drug Name |
ADX-48621
|
|||
| Synonyms |
Dipraglurant; 872363-17-2; UNII-CV8JZR21A1; ADX48621; CV8JZR21A1; CHEMBL2346738; 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine; Dipraglurant [INN]; ADX-48621; SCHEMBL103033; GTPL6452; C16H12FN3; DTXSID90236230; BCP23706; BDBM50431705; ZINC72266314; 3590AH; 6-Fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine; AKOS030526956; SB16993; DB12733; CS-0690; NCGC00351745-02; HY-14859; DB-076892; FT-0705373; J3.560.334D; W-5761; ADX 48621;ADX48621;ADX-48621
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2/3 | [1] | |
| Dyskinesia [ICD-11: MB47.4] | Phase 2 | [2] | ||
| Mood disorder [ICD-11: 6A60-6E23] | Phase 2 | [3], [4] | ||
| Company |
Addex Pharma.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H12FN3
|
|||
| Canonical SMILES |
C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F
|
|||
| InChI |
1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
|
|||
| InChIKey |
LZXMUJCJAWVHPZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 872363-17-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04857359) Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6452). | |||
| REF 4 | ClinicalTrials.gov (NCT01336088) ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease. U.S. National Institutes of Health. | |||
| REF 5 | Pipeline of Addex Pharma. Addex Pharma. 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.